medRxiv
Cure8 research brief
Why This Matters
AI tools like Google NotebookLM could make systematic reviews and consensus statement processes faster and less labor-intensive for IBD-related evidence, while maintaining very low rates of major factual errors.
Patients and clinicians may see accelerated synthesis of evidence that informs guidelines, but human checking remains necessary to catch omissions.
Who Should Pay Attention
Researchers conducting systematic reviews or guideline panels in IBD and related metabolic comorbidity areas; clinical methodologists and guideline developers; clinicians who rely on rapidly produced evidence syntheses.
Study Snapshot
Story typeResearch paper
Evidence typePreprint
Study statusPreprint
Source depthJournal abstract
What To Know
This paper examines whether a Google LLM tool can speed up and assist complex evidence extraction and consensus-statement drafting for a multidisciplinary IBD-related review. The authors report large time savings and low rates of major factual errors, but note that missing or incomplete extractions were the main limitation and required human review.
The workflow combined structured prompting (PICO) with human validation: AI produced candidate data cells and draft statements, while independent reviewers checked and corrected outputs against source full texts. Roughly half of finalized consensus statements originated from AI drafts and most were retained after expert editing.
These findings are described in a medRxiv preprint (abstract-level extraction provided); the work is methodological and does not change clinical care. The tool’s performance may vary with different review topics, prompt design, or AI updates; human
Keep In Mind
This is a preprint (medRxiv) and represents a methodological report based on an abstract-level extraction. The authors emphasize that extractive incompleteness (omissions/incomplete fields) was the primary limitation and that human review/validation was part of the workflow. Results may not generalize to all topics, LLM versions, or prompt strategies.
Summary grounded in the provided abstract; full peer-reviewed assessment is not available.
Source Details
Review the original publication for the complete reporting, methods, and context.
Preprint
Evidence type derived from source or registry metadata.
PublicationmedRxiv
AuthorsSamaan, S., Devi, J., Vincent, M. +8 more
Study typePublishaheadofprint
Indexed viamedRxiv
Source typePreprint
PublishedJun 26, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Novel SLC10A2 variants induce primary bile acid malabsorption and dysbiosis with IBD-like features.
Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn's ...
The story describes a new drug mechanism (dCK inhibition) that reduced inflammation in an IBD mouse model, which could point to a different way to target overactive immune cells in Crohn’s disease. It’s early-stage...
Crosstalk between circRNAs and the classic signaling pathways in IBD.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.